Insider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad sold 3,806 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $6.27, for a total transaction of $23,863.62. Following the completion of the sale, the director now owns 20,000 shares of the company’s stock, valued at approximately $125,400. This trade represents a 15.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Design Therapeutics Stock Up 0.7 %

Shares of Design Therapeutics stock traded up $0.04 during trading on Thursday, reaching $5.99. The company’s stock had a trading volume of 296,400 shares, compared to its average volume of 235,578. Design Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $7.77. The company has a 50-day simple moving average of $5.85 and a two-hundred day simple moving average of $4.96. The company has a market cap of $339.16 million, a price-to-earnings ratio of -7.05 and a beta of 1.86.

Institutional Investors Weigh In On Design Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. raised its position in shares of Design Therapeutics by 58.3% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock valued at $10,182,000 after purchasing an additional 697,368 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Design Therapeutics by 2.9% in the third quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company’s stock worth $9,381,000 after buying an additional 48,431 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Design Therapeutics by 61.6% during the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock worth $8,612,000 after buying an additional 609,939 shares during the period. Almitas Capital LLC grew its holdings in shares of Design Therapeutics by 22.1% during the second quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock valued at $4,198,000 after buying an additional 227,180 shares during the last quarter. Finally, FMR LLC increased its position in shares of Design Therapeutics by 922.8% in the 3rd quarter. FMR LLC now owns 828,665 shares of the company’s stock valued at $4,458,000 after acquiring an additional 747,649 shares during the period. Institutional investors and hedge funds own 56.64% of the company’s stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.